BioLineRx (BLRX) FCF Margin (2023 - 2025)
Historic FCF Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 493.21%.
- BioLineRx's FCF Margin fell 2944400.0% to 493.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 105.93%, marking a year-over-year increase of 598700.0%. This contributed to the annual value of 151.42% for FY2024, which is 3171700.0% up from last year.
- Latest data reveals that BioLineRx reported FCF Margin of 493.21% as of Q3 2025, which was down 2944400.0% from 58.22% recorded in Q2 2025.
- In the past 5 years, BioLineRx's FCF Margin ranged from a high of 1267.3% in Q1 2023 and a low of 1182.8% during Q3 2023
- Over the past 3 years, BioLineRx's median FCF Margin value was 202.06% (recorded in 2024), while the average stood at 168.01%.
- Data for BioLineRx's FCF Margin shows a peak YoY increase of 9840300bps (in 2024) and a maximum YoY decrease of -14726600bps (in 2024) over the last 5 years.
- BioLineRx's FCF Margin (Quarter) stood at 489.92% in 2023, then plummeted by -115bps to 73.33% in 2024, then crashed by -573bps to 493.21% in 2025.
- Its last three reported values are 493.21% in Q3 2025, 58.22% for Q2 2025, and 1016.08% during Q1 2025.